Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic antipyretics and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants
2010-022303-22Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jun 2011
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in pneumococcal disease comparing PCV13 + prophylactic paracetamol, PCV13 + prophylactic ibuprofen and PCV13 without prophylactic antipyretic (3 arms). Primary endpoint: Serotype-specific IgG geometric mean concentrations. Started Jun 2011; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccineacetaminophenibuprofen
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2010-022303-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022303-22.